Terms: = Thyroid cancer AND RET, RET51, 5979, P07949, ENSG00000165731, MTC1, MEN2A, RET-ELE1, HSCR1, MEN2B, CDHF12
2814 results:
1.
Prabhash K; Saldanha E; Patil V; Bal M; Reddy P S; Sanjeev A; Kumar R; Poojary D; Noronha V; Menon N; Mittal N; Trivedi V; Nambiar K; Mishra R; Tanwar N; Malhotra R; Pange P; Gupta V; Veldore VH; Chougule A; Chaturvedi P; Dutt A; Chandrani P
JCO Precis Oncol; 2024 May; 8():e2300622. PubMed ID: 38754058
[TBL] [Abstract] [Full Text] [Related]
2. Next-generation sequencing identified that ret variation associates with lymph node metastasis and the immune microenvironment in thyroid papillary carcinoma.
Huang Y; Lin P; Liao J; Liang F; Han P; Fu S; Jiang Y; Yang Z; Tan N; Huang J; Chen R; Ouyang N; Huang X
BMC Endocr Disord; 2024 May; 24(1):68. PubMed ID: 38734621
[TBL] [Abstract] [Full Text] [Related]
3. Timing and Ideal Patient for an Appropriate Search for Somatic
Matrone A; Prete A; Gambale C; Elisei R
JCO Precis Oncol; 2024 May; 8():e2400017. PubMed ID: 38709990
[TBL] [Abstract] [Full Text] [Related]
4. Spontaneous and Treatment-Related Changes of Serum Calcitonin in Medullary thyroid cancer: Long-Term Experience in a Patient With Multiple Endocrine Neoplasia Type 2B.
Réti Z; Tabák ÁG; Garami M; Kalina I; Kiss G; Sápi Z; Tóth M; Tőke J
JCO Precis Oncol; 2024 May; 8():e2300675. PubMed ID: 38709988
[TBL] [Abstract] [Full Text] [Related]
5. Management of Advanced Medullary thyroid Carcinoma: Current Systemic Therapy Options.
Jara MA
Crit Rev Oncog; 2024; 29(3):83-90. PubMed ID: 38683155
[TBL] [Abstract] [Full Text] [Related]
6. Predictors of radioiodine (RAI)-avidity restoration for NTRK fusion-positive RAI-resistant metastatic thyroid cancers.
Syed AR; Gorana A; Nohr E; Yuan XK; Amin MASc P; Ghaznavi S; Lamb D; McIntyre J; Eszlinger M; Paschke R
Eur Thyroid J; 2024 Jun; 13(3):. PubMed ID: 38642578
[TBL] [Abstract] [Full Text] [Related]
7. Integrated proteogenomic and metabolomic characterization of papillary thyroid cancer with different recurrence risks.
Qu N; Chen D; Ma B; Zhang L; Wang Q; Wang Y; Wang H; Ni Z; Wang W; Liao T; Xiang J; Wang Y; Jin S; Xue D; Wu W; Wang Y; Ji Q; He H; Piao HL; Shi R
Nat Commun; 2024 Apr; 15(1):3175. PubMed ID: 38609408
[TBL] [Abstract] [Full Text] [Related]
8. Anaplastic and poorly differentiated thyroid carcinomas: genetic evidence of high-grade transformation from differentiated thyroid carcinoma.
Gu H; Wang J; Ran W; Li G; Hu S; Zhao H; Wang X; Wang J
J Pathol Clin Res; 2024 Mar; 10(2):e356. PubMed ID: 38602501
[TBL] [Abstract] [Full Text] [Related]
9. BRAF and ret polymorphism association with thyroid cancer risk, a preliminary study from Khyber Pakhtunkhwa population.
Batool M; Khan NU; Khan H; Almutairi MH; Ali I; Adams BD
Mol Biol Rep; 2024 Apr; 51(1):502. PubMed ID: 38598020
[TBL] [Abstract] [Full Text] [Related]
10. Correlation Between the Clinicopathological Features of Papillary thyroid Carcinoma Complicated with Hashimoto's thyroiditis, BRAF V600E Gene Mutation, and ret Gene Rearrangement.
Xie M; Xu ZX; Dai M; Zhu YY
J Coll Physicians Surg Pak; 2024 Apr; 34(4):445-450. PubMed ID: 38576288
[TBL] [Abstract] [Full Text] [Related]
11. Advances in targeted therapy and biomarker research in thyroid cancer.
Guo M; Sun Y; Wei Y; Xu J; Zhang C
Front Endocrinol (Lausanne); 2024; 15():1372553. PubMed ID: 38501105
[TBL] [Abstract] [Full Text] [Related]
12. Accelerated men2a in homozygous ret carriers in the context of consanguinity.
Machens A; Dralle H
Eur J Endocrinol; 2024 Mar; 190(3):K43-K46. PubMed ID: 38465999
[TBL] [Abstract] [Full Text] [Related]
13. External beam radiation therapy for recurrent or residual thyroid cancer: What is the best treatment time and the best candidate for long-term local disease control?
Cavalcante LBCP; Treistman N; Gonzalez FMTT; Fernandes PIW; Alves Junior PAG; Andrade FA; Ferreira EN; Brito TF; Pane A; Corbo R; Erlich F; Bulzico DA; Vaisman F
Head Neck; 2024 Jun; 46(6):1340-1350. PubMed ID: 38445804
[TBL] [Abstract] [Full Text] [Related]
14. [Stratified application of gene expression in diagnosis of thyroid nodules].
Guan WY; Zheng JY; Nie L; Wu HY
Zhonghua Bing Li Xue Za Zhi; 2024 Mar; 53(3):264-268. PubMed ID: 38433054
[No Abstract] [Full Text] [Related]
15. Generating Potential ret-Specific Inhibitors Using a Novel LSTM Encoder-Decoder Model.
Liu L; Zhao X; Huang X
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397034
[TBL] [Abstract] [Full Text] [Related]
16. The role of prophylactic parathyroidectomy during thyroidectomy for MTC in patients with men2a syndrome.
Kavazis C; Romanidis K; Pitiakoudis M; Kesisoglou I; Laskou S; Sapalidis K
Folia Med (Plovdiv); 2023 Oct; 65(5):720-727. PubMed ID: 38351753
[TBL] [Abstract] [Full Text] [Related]
17. ret kinase inhibitors for the treatment of ret-altered thyroid cancers: Current knowledge and future directions.
Hamidi S; Hu MI
Ann Endocrinol (Paris); 2024 Apr; 85(2):118-126. PubMed ID: 38342224
[TBL] [Abstract] [Full Text] [Related]
18. The Pathogenic ret Val804Met Variant in Acromegaly: A New Clinical Phenotype?
Chiloiro S; Capoluongo ED; Costanza F; Minucci A; Giampietro A; Infante A; Milardi D; Ricciardi Tenore C; De Bonis M; Gaudino S; Rindi G; Olivi A; De Marinis L; Pontecorvi A; Doglietto F; Bianchi A
Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339173
[TBL] [Abstract] [Full Text] [Related]
19. Integrated budget impact model to estimate the impact of introducing selpercatinib as a tumor-agnostic treatment option for patients with
Bhandari NR; Gilligan AM; Myers J; Ale-Ali A; Smolen L
J Med Econ; 2024; 27(1):348-358. PubMed ID: 38334069
[TBL] [Abstract] [Full Text] [Related]
20. Updates on the genetics of multiple endocrine neoplasia.
Sahakian N; Castinetti F; Romanet P; Reznik Y; Brue T
Ann Endocrinol (Paris); 2024 Apr; 85(2):127-135. PubMed ID: 38325596
[TBL] [Abstract] [Full Text] [Related]
[Next]